OKYO Pharma Limited

NASDAQ:OKYO

1.52 (USD) • At close May 17, 2024
Bedrijfsnaam OKYO Pharma Limited
Symbool OKYO
Munteenheid USD
Prijs 1.52
Beurswaarde 48,563,228
Dividendpercentage 0%
52-weken bereik 0.92 - 3.07
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gary S. Jacob Ph.D.
Website https://www.okyopharma.com

An error occurred while fetching data.

Over OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue

Vergelijkbare Aandelen

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

2.675 USD

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

1.65 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

8.26 USD

NexImmune, Inc. logo

NexImmune, Inc.

NEXI

3.336 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

1.01 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)